INCY - BriaCell/Incyte opens enrollment for Phase I/IIa combo study in breast cancer

BriaCell Therapeutics (BCTX) announces the open recruitment and enrollment of their collaborative clinical study with Incyte (INCY).The Phase I/IIa combination study is designed to evaluate BriaCell’s lead candidate, Bria-IMT, with Incyte’s checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer. The BriaCell and Incyte clinical program is a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates. BriaCell and Incyte had previously treated two patients under this Phase I/IIa combination study subsequent to the collaboration in April 2019. Some of those patients were included in BriaCell’s recent survival data announcement. With funding now secured, BriaCell has once again opened this collaborative study to enrollment.BCTX shares up 4.3% premarket at $6.10.

For further details see:

BriaCell/Incyte opens enrollment for Phase I/IIa combo study in breast cancer